Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (~30%) will undergo imaging with standardized intervals.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Osimertinib plus chemo, or other regimens | Osimertinib plus chemo, or other regimens in the metastatic setting initiated on or after January 1, 2024 | ||
| Osimertinib monotherapy | Osimertinib monotherapy for newly diagnosed mNSCLC |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Assess real world progression-free survival in patients with locally advanced or metastatic NSCLC treated with first line osimertinib | From the index date (date of initiation of first line treatment for metastatic disease) until date of progression or date of death whichever comes first, assessed up to 100 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Assess overall survival in patients with locally advanced or metastatic NSCLC treated with first line osimertinib | From the index date (date of initiation of first line treatment for metastatic disease) until death, as assessed up to 100 months | |
| Assess time to treatment discontinuation in patients with locally advanced or metastatic NSCLC treated with first line osimertinib |
Not provided
INCLUSION CRITERIA
EXCLUSION CRITERIA
Not provided
Not provided
Not provided
All patients diagnosed with EGFR mutant locally advanced or metastatic NSCLC diagnosed from Jan 1st 2024 until the enrollment period ends.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| N-Power Medicine Support | Contact | 1-833-467-6734 | support@npowermedicine.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pacific Cancer Care | Recruiting | Monterey | California | 93940 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| From the index date (date of initiation of first line treatment for metastatic disease) until treatment discontinuation, as assessed up to 100 months |
| Torrance Memorial Physician Network-Cancer Care | Recruiting | Torrance | California | 90505 | United States |
|
| Bayhealth Cancer Center- Kent | Recruiting | Dover | Delaware | 19901 | United States |
|
| Bayhealth Cancer Center- Sussex | Recruiting | Milford | Delaware | 19963 | United States |
|
| Kootenai Clinic Cancer Services Coeur d'Alene | Recruiting | Coeur d'Alene | Idaho | 83814 | United States |
|
| Northwest Oncology & Hematology | Recruiting | Elk Grove Village | Illinois | 60007 | United States |
|
| Lankenau Medical Center | Not yet recruiting | Paoli | Pennsylvania | 19301 | United States |
|
| Oncology Consultants, P.A. | Recruiting | Houston | Texas | 77030 | United States |
|
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D009362 | Neoplasm Metastasis |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided